Summary of studies evaluating thrombophilia as risk factor of deep vein thrombosis of the upper extremities
| First author (reference) . | Patients/controls . | Deaths . | PE . | Recurrence . | Risk factors . |
|---|---|---|---|---|---|
| Martinelli (43,44) | 115/797 | NR | NR | 12/98 (12%) | PT, PC, PS and AT were associated with 5-fold increased risk, FVL with 6-fold increased risk |
| Prandoni (45) | 53/0 | 11/53 (21%) | 1/53 (2%) | 3/53 (6%) | 12 patients (22.6%) had inherited thrombophilia (6 FVL, 3 PC, 2 AT, 1 PT) |
| Blom (46) | 179/2399 | NR | NR | NR | PT and FVL associated with 2-fold increased risk; synergistic effect between mutations and acquired risk factors (oral contraceptive use, cancer, surgery) |
| Baarslag (47) | 50/33 | 25/50 (50%) | NR | 4/50 (8%) | 6 of 30 (20%) investigated patients (20%) had inherited thrombophilia (3 FVL, 2 PS, 1 PT) |
| Heron (52) | 51/0 | NR | 11/51 (21%) | 2/51 (4%) | 7 patients (23%) had inherited thrombophilia (5 FVL, 2 PS) |
| Hendler (53) | 31/0 | NR | NR | NR | 19 patients (61%) had one or more thrombophilic abnormality (4 FVL, 3 PT, 1 PS, 14 APA, 5 HHcy) |
| Leebeek (54) | 41/0 | NR | 2/41 (5%) | 1/41 (2%) | 15 patients (32%) had one or more thrombophilic abnormality (2 FVL, 1 AT, 11 APA, 1 combination) |
| Vaya (55) | 79/165 | NR | NR | NR | 12 patients (15%) had inherited thrombophilia (9 PT, 3 FVL). Synergistic effect between mutations and oral contraceptive use |
| First author (reference) . | Patients/controls . | Deaths . | PE . | Recurrence . | Risk factors . |
|---|---|---|---|---|---|
| Martinelli (43,44) | 115/797 | NR | NR | 12/98 (12%) | PT, PC, PS and AT were associated with 5-fold increased risk, FVL with 6-fold increased risk |
| Prandoni (45) | 53/0 | 11/53 (21%) | 1/53 (2%) | 3/53 (6%) | 12 patients (22.6%) had inherited thrombophilia (6 FVL, 3 PC, 2 AT, 1 PT) |
| Blom (46) | 179/2399 | NR | NR | NR | PT and FVL associated with 2-fold increased risk; synergistic effect between mutations and acquired risk factors (oral contraceptive use, cancer, surgery) |
| Baarslag (47) | 50/33 | 25/50 (50%) | NR | 4/50 (8%) | 6 of 30 (20%) investigated patients (20%) had inherited thrombophilia (3 FVL, 2 PS, 1 PT) |
| Heron (52) | 51/0 | NR | 11/51 (21%) | 2/51 (4%) | 7 patients (23%) had inherited thrombophilia (5 FVL, 2 PS) |
| Hendler (53) | 31/0 | NR | NR | NR | 19 patients (61%) had one or more thrombophilic abnormality (4 FVL, 3 PT, 1 PS, 14 APA, 5 HHcy) |
| Leebeek (54) | 41/0 | NR | 2/41 (5%) | 1/41 (2%) | 15 patients (32%) had one or more thrombophilic abnormality (2 FVL, 1 AT, 11 APA, 1 combination) |
| Vaya (55) | 79/165 | NR | NR | NR | 12 patients (15%) had inherited thrombophilia (9 PT, 3 FVL). Synergistic effect between mutations and oral contraceptive use |
PE indicates pulmonary embolism; NR, not reported; FVL, factor V Leiden; PT, prothrombin G20210A mutation; PC, protein C deficiency; PS, protein S deficiency; AT, antithrombin deficiency; APA, antiphospholipid antibodies; and HHcy, hyperhomocysteinemia.